文献速递头颈部肿瘤放疗

淋巴结阳性颈部IMRT差异化剂量照射的安全性

Safety of differential radiation dosing in lymph node positive necks treated with IMRT.
PubMed 文献 · Pract Radiat Oncol · 2017-07-19

本研究纳入2个学术医学中心2004至2016年接受IMRT治疗的HNSCC患者,评估将中间剂量限制于最上及最下受累淋巴结上下2 cm区域、其余颈部接受标准剂量的安全性。57侧颈部中17.5%在治疗后2年内出现颈部复发,所有失败均位于该2 cm边界内,边界外无失败(95%CI 0-7.7)。结果支持仅对邻近大体颈部病变区域给予中间剂量、其余颈部给予较低标准剂量的可行性。

要点

  • 57侧淋巴结阳性颈部IMRT后2年内颈部复发率为17.5%。
  • 所有颈部失败均位于最上及最下受累淋巴结上下2 cm范围内。
  • 该2 cm边界外无失败,95%CI为0-7.7。

核心结论

  • 结果支持仅对邻近大体颈部病变区域给予中间剂量、其余颈部给予较低标准剂量的可行性。

研究设计与样本

  • 回顾性识别2个学术医学中心2004至2016年接受IMRT治疗的HNSCC患者,共分析57侧颈部。
  • 中间剂量限制于最上及最下受累淋巴结上下2 cm区域,更远端颈部接受标准剂量。
  • 计算 demographics 和临床特征的描述性统计,以及治疗后2年失败比例。
  • 通过修改的泊松分布计算置信区间判定中间剂量区域外失败。

主要发现

  • 57侧颈部中17.5%在完成治疗后2年内出现颈部疾病复发。
  • 所有失败均位于最上及最下受累淋巴结上下2 cm边界内。
  • 该2 cm边界外无失败,95%CI为0-7.7。

关键数值与推荐

  • 中间剂量范围为最上及最下受累淋巴结上下2 cm区域。
  • 大体肿瘤接受全剂量66-70 Gy,较高风险颈部区域接受中间剂量59-63 Gy,较低风险颈部区域接受标准剂量50-54 Gy。

临床怎么用

  • 可考虑仅对邻近大体颈部病变区域给予中间剂量,其余颈部给予较低标准剂量。
  • 该治疗范式仍需额外研究验证。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: When treating head and neck squamous cell carcinoma (HNSCC) with intensity modulated radiation therapy (IMRT), it is common to use several dose levels for a lymph node positive neck: full dose (66-70 Gy) to gross cancer, intermediate dose (59-63 Gy) to higher risk neck regions, and standard dose (50-54 Gy) to lower risk neck regions. There is no consensus regarding how much of the neck should receive intermediate versus standard dose, however. METHODS AND MATERIALS: HNSCC patients treated with IMRT were identified from 2 academic medical centers between 2004 and 2016. Intermediate dose was restricted to a region of the neck 2 cm above and below the most superior and inferior involved lymph nodes; standard dose was delivered to more distal neck regions. Descriptive statistics were calculated for demographics and clinical characteristics as well as proportions for failures 2 years after treatment. Failure outside the intermediate dose region was determined by calculating confidence intervals from a modification of the Poisson distribution. RESULTS: Of the 57 necks included in this study, 17.5% experienced disease recurrence in the neck within 2 years of completing treatment. All failures were within the 2-cm margin above or below the most superior and inferior involved nodes; there were no failures outside this 2-cm margin (95% confidence interval, 0-7.7). CONCLUSIONS: The results of this study support the feasibility of treating only the neck adjacent to gross neck disease to an intermediate dose, and treating the remainder of the neck to a lower, standard dose. Although these results are encouraging, additional study of this treatment paradigm is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sozio S, Rivera-Núñez Z, Mahmoud O, et al. Safety of differential radiation dosing in lymph node positive necks treated with IMRT. Pract Radiat Oncol. 2017. PMID: 28919248. doi:10.1016/j.prro.2017.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。